FMA
DCPH

FNY Managed Accounts’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

FNY Managed Accounts’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-8,100
Closed -$153K – 862
2017
Q3 		$153K Buy
+8,100
New +$148K 0.2% 81

Other funds holding DCPH

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

FNY Managed Accounts's DCPH Position: Q4 2017 in Review

FNY Managed Accounts sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q4 2017, closing a stake of 8,100 shares — an estimated $153K sold.

FNY Managed Accounts first reported a position in DCPH in Q3 2017 and held it in 1 quarter. The position peaked at $153K in Q3 2017. 59 funds tracked by Wall St. Rank hold DCPH as of Q4 2017.

  • FNY Managed Accounts reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • FNY Managed Accounts sold 8,100 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q4 2017, an estimated $153K.
  • FNY Managed Accounts first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • FNY Managed Accounts's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $153K in Q3 2017.
  • 59 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q4 2017.

Based on FNY Managed Accounts's 13F filing for Q4 2017, filed 23 Jan 2018.